

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***  
**NDA 20-164/S-030**

***Name:*** Lovenox® (Enoxaparin Sodium) Injection

***Sponsor:*** Aventis Pharmaceuticals Products Inc.

***Approval Date:*** June 2, 2000

# CENTER FOR DRUG EVALUATION AND RESEARCH

***APPLICATION NUMBER:***  
**NDA 20-164/S-030**

## CONTENTS

<b>Reviews / Information Included in this Review</b>
--

<b>Approval Letter</b>	<b>X</b>
<b>Approvable Letter</b>	<b>X</b>
<b>Labeling</b>	<b>X</b>
<b>Labeling Review</b>	<b>X</b>
<b>Medical Review</b>	
<b>Chemistry Reviews</b>	<b>X</b>
<b>Pharmacology / Toxicology Review</b>	
<b>Statistical Review</b>	
<b>Microbiology Review</b>	<b>X</b>
<b>Clinical Pharmacology / Biopharmaceutics Review</b>	<b>X</b>
<b>Administrative and Correspondence Documents</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*  
**NDA 20-164/S-030**

**APPROVAL LETTER**

126.1

NDA 20-164/S-030

JUN 2 2000

Aventis Pharmaceuticals Products Inc.  
Attention: Edmond Roland, Ph.D.  
500 Arcola Road  
P.O. Box 1200  
Collegeville, PA 19426-0107

Dear Dr. Roland:

Please refer to your supplemental new drug application dated July 6, 1999, received July 8, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lovenox® (enoxaparin sodium) Injection.

We acknowledge receipt of your submission of December 29, 1999, that constituted a complete response to our December 13, 1999 action letter.

This supplemental new drug application provides for the following change: qualification of a new concentration of Lovenox® (enoxaparin sodium) Injection, 150mg/mL solution of enoxaparin sodium in Water for Injection, to supply 90 mg/0.6mL, 120mg/0.8mL, and 150 mg/1mL pre-filled syringes.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text submitted, and with the minor editorial revisions listed below. Accordingly, the supplemental application is approved effective on the date of this letter.

PACKAGE INSERT

1. In the DESCRIPTION section, delete the phrase "Each dosage unit of" in the following sentences to read:

**Lovenox Injection 100 mg/mL Concentration** contains 10 mg enoxaparin sodium (or approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

**Lovenox Injection 150 mg/mL Concentration** contains 15 mg enoxaparin sodium (or approximate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

2. After the HOW SUPPLIED section, revise the name of the manufacturer to read "Aventis Pharmaceuticals Products Inc."

#### IMMEDIATE CONTAINER LABELS

3. Provide more distinctive colors for the visual differentiation of the strengths of the various drug products. Specifically, the purple and blue colors used in Lovenox 120 and Lovenox 150 labels are quite similar and could be easily confused.
4. Provide identical color (as much as possible) across a specific package line (i.e., the 90 mg/0.6 mL [150 mg/mL Concentration] immediate container label, blister, and carton).
5. Revise the name of the manufacturer to read "Aventis Pharmaceuticals Products Inc."

#### BLISTER LABELS

6. Delete \_\_\_\_\_
7. Revise the name of the manufacturer to read "Aventis Pharmaceuticals Products Inc."

#### CARTONS

8. Revise the name of the manufacturer to read "Aventis Pharmaceuticals Products Inc."

The Agency wishes to advise you that the phrase "NEW CONCENTRATION" on the cartons should be deleted after 6 months. Further, consider moving the "Rx Only" phrase from the back panel to the front panel of the cartons.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the submitted draft labeling (package insert submitted December 29, 1999, immediate container and carton labels submitted December 29, 1999). These revisions are terms of the approval of this application.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. The submission should include the appropriate number of copies of the package insert from both the Maison-Alfort and the Dagenham printing sites. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-164/S-030." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

Finally, the Agency wishes to advise you that the proposed labeling changes to the prefilled syringes (30 mg/0.3 mL and 40 mg/0.4 mL, the graduated prefilled syringes (60 mg/0.6mL, 80 mg/0.8mL, and 100 mg/1mL), and ampule (30 mg/0.3mL) outlined in your December 29, 1999 submission (pages 1-146-1-152) will require a supplemental application to the NDA.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Karen Oliver, Regulatory Project Manager, at (301) 827-7457.

Sincerely,

*LT 6-6-00*

Lilia Talarico, M.D.  
Director  
Division of Gastrointestinal and Coagulation Drug  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

cc:

Archival NDA 20-164/S-030

HFD-180/Div. Files

HFD-180/K.Oliver

HFD-180/L.Talarico

HFD-180/L.Zhou

HFD-180/J.Sieczkowski

HF-2/MedWatch (with labeling)

HFD-002/ORM (with labeling)

HFD-103/ADRA (with labeling)

HFD-40/DDMAC (with labeling)

HFI-20/Press Office (with labeling)

HFD-400/OPDRA (with labeling)

HFD-613/OGD (with labeling)

HFD-21/ACS (with labeling) - ONLY for drug discussed at advisory committee meeting.

HFD-095/DDMS-IMT (with labeling)

HFD-820/DNDC Division Director

DISTRICT OFFICE

Drafted by: KO/May 24, 2000

Initialed by: J.Sieczkowski 05/26/00

Initialed by: L.Zhou 05/26/00

Initialed by: L.Talarico 05/29/00

final: KO/05/30/00/c:\data\mydocuments\NDA20164-S-030-05-24-00-AP.DOC *K.Oliver 05/30/00*

APPROVAL (AP)



**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*  
**NDA 20-164/S-030**

**APPROVABLE LETTER**

NDA 20-164/S-030

Rhone-Poulenc Rorer Pharmaceuticals Inc.  
Attention: Mr. Dennis Jurgens  
500 Arcola Avenue  
P.O. Box 1200  
Collegeville, PA 19426-0107

DEC 13 1999

Dear Mr. Jurgens:

Please refer to your supplemental new drug application dated July 6, 1999, received July 8, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lovenox® (enoxaparin sodium) Injection.

This supplement proposes the following change: qualification of a new concentration of Lovenox® (enoxaparin sodium) Injection, 150 mg/mL solution of enoxaparin sodium in Water for Injection, to supply 90 mg/0.6mL, 120mg/0.8mL, and 150mg/1mL pre-filled syringes.

We have completed the review of this application and it is approvable. Before this application may be approved, however, it will be necessary for you to address the following:

1. Provide an adequate response to the November 18, 1999 information request letter.
2. Submit revised draft package insert labeling as follows:
  - a. In the CLINICAL PHARMACOLOGY section, the "Pharmacodynamics" subsection, delete the sentences \_\_\_\_\_" and insert the following sentences to read:

Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin dose. When a daily 1.5 mg/kg SC injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration, the following pharmacokinetic profiles were obtained (see table below).
  - b. In the DESCRIPTION section, delete the following dosing information from this section (as requested in the November 18, 1999 information request letter):

[

]

[ ]

Further comments on the labeling for the cartons, immediate container, and package insert will be provided after tradename, logo design, and nomenclature issues (identified in the November 18, 1999 information request letter) have been resolved, and revised draft labeling has been submitted.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.

If you have any questions, contact Karen Oliver, Project Manager, at (301) 827-7457.

Sincerely,

LT 12-13-99

Lilia Talarico, M.D.  
Director  
Division of Gastrointestinal and Coagulation Drug  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

cc:

Archival NDA 20-164/S-030

HFD-180/Div. Files

HFD-180/K.Oliver

HFD-180/L.Talarico

HFD-180/L.Zhou

HFD-180/J.Sieczkowski

DISTRICT OFFICE

Drafted by: KO/December 10, 1999

Initialed by: L.Zhou 12/10/99

Initialed by: L.Talarico 12/10/99 *KO Oliver 12/13/99*

final: KO/12/13/99/c:\data\mydocuments\NDA20-164-S-030-12-10-99-ae.doc

APPROVABLE (AE)

**CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***  
**NDA 20-164/S-030**

**LABELING**

**SPINAL / EPIDURAL HEMATOMAS**

When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with low molecular weight heparins or heparinoids for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events is increased by the use of indwelling epidural catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis such as non steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants. The risk also appears to be increased by traumatic or repeated epidural or spinal puncture.

Patients should be frequently monitored for signs and symptoms of neurological impairment. If neurologic compromise is noted, urgent treatment is necessary.

The physician should consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis (see also **WARNINGS, Hemorrhage, and PRECAUTIONS, Drug Interactions**).

**DESCRIPTION**

Lovenox Injection is a sterile solution containing enoxaparin sodium, a low molecular weight heparin.

Lovenox Injection is available in two concentrations:

**1 100 mg per mL of Water for Injection**

- Prefilled Syringes 30 mg / 0.3 mL, 40 mg / 0.4 mL
- Graduated Prefilled Syringes 60 mg / 0.6 mL, 80 mg / 0.8 mL, 100 mg / 1 mL
- Ampules 30 mg / 0.3 mL

**Lovenox Injection 100 mg/mL Concentration** contains 10 mg enoxaparin sodium (or approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

**2 150 mg per mL of Water for Injection**

- Graduated Prefilled Syringes 120 mg / 0.8 mL, 150 mg / 1 mL


**Lovenox Injection 150 mg/mL Concentration** contains 15 mg enoxaparin sodium (or appropriate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

The solutions are preservative-free and intended for use only as a single-dose injection. (See **DOSE AND ADMINISTRATION** and **HOW SUPPLIED** for dosage unit descriptions.) The pH of the injection is 5.5 to 7.5. Nitrogen is used in the headspace to inhibit oxidation.

Enoxaparin is obtained by alkaline degradation of heparin bistrimethyl ester derived from porcine intestinal mucosa. Its structure is characterized by a 2-O-sulfo-4-enepryanosuronic acid group at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine at the reducing end of the chain. The substance is the sodium salt. The average molecular weight is about 4500 daltons. The molecular weight distribution is:

<2000 daltons	≤20%
2000 to 8000 daltons	≥68%
>8000 daltons	≤18%

**STRUCTURAL FORMULA**



**CLINICAL PHARMACOLOGY**

Enoxaparin is a low molecular weight heparin which has antithrombotic properties. In humans, enoxaparin given at a dose of 1.5 mg/kg subcutaneously (SC) is characterized by a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean±SD, 14.0±3.1) (based on areas under anti-Factor activity versus time curves) compared to the ratios observed for heparin (mean±SD, 1.22±0.13). Increases of up to 1.8 times the control values were seen in the thrombin time (TT) and the activated partial thromboplastin time (aPTT). Enoxaparin at a 1 mg/kg dose (100 mg / mL concentration), administered SC every 12 hours to patients in a large clinical trial resulted in aPTT values of 45 seconds or less in the majority of patients (n = 1607).

**Pharmacodynamics** (conducted using 100 mg / mL concentration): Maximum anti-Factor Xa and antithrombin (anti-Factor IIa) activities occur 3 to 5 hours after SC injection of enoxaparin. Mean peak anti-Factor Xa activity was 0.16 IU/mL (1.58 µg/mL) and 0.38 IU/mL (3.83 µg/mL) after the 20 mg and the 40 mg clinically tested SC doses, respectively. Mean (n = 46) peak anti-Factor Xa activity was 1.1 IU/mL at steady state in patients with unstable angina receiving 1mg/kg SC every 12 hours for 14 days. Mean absolute bioavailability of enoxaparin, given SC, based on anti-Factor Xa activity is 92% in healthy volunteers. The volume of distribution of anti-Factor Xa activity is about 6 L. Following intravenous (i.v.) dosing, the total body clearance of enoxaparin is 26 mL/min. After i.v. dosing of enoxaparin labeled with the gamma-emitter, <sup>99m</sup>Tc, 40% of radioactivity and 8 to 20% of anti-Factor Xa activity were recovered in urine in 24 hours. Elimination half-life based on anti-Factor Xa activity was 4.5 hours after SC administration. Following a 40 mg SC once a day dose, significant anti-Factor Xa activity persists in plasma for about 12 hours.

Following SC dosing, the apparent clearance (CL/F) of enoxaparin is approximately 15 mL/min. Apparent clearance and A<sub>max</sub> derived from anti-Factor Xa values following single SC dosing (40 mg and 60 mg) were slightly higher in males than in females. The source of the gender difference in these parameters has not been conclusively identified, however, body weight may be a contributing factor.

Apparent clearance and A<sub>max</sub> derived from anti-Factor Xa values following single and multiple SC dosing in elderly subjects were close to those observed in young subjects. Following once a day SC dosing of 40 mg enoxaparin, the Day 10 mean area under anti-Factor Xa activity versus time curve (AUC) was approximately 15% greater than the mean Day 1 AUC value. In subjects with moderate renal impairment (creatinine clearance 30 to 80 mL/min), anti-Factor Xa CL/F values were similar to those in healthy subjects. However, mean CL/F values of subjects with severe renal impairment (creatinine clearance <30 mL/min), were approximately 30% lower than the mean CL/F value of control group subjects. (See **PRECAUTIONS**.)

Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin concentration. When a daily 1.5 mg/kg SC injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration the following pharmacokinetic profiles were observed (see table below):

**Pharmacokinetic Parameters\* After 5 Days of 1.5 mg/kg SC Once Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations**

	Concentration	Anti-Xa	Anti-IIa	HepTest	aPTT
<b>A<sub>max</sub></b> (IU/mL or Δ sec)	100 mg/mL	1.37 (±0.23)	0.23 (±0.05)	104.5 (±16.6)	19.3 (±4.7)
	200 mg/mL	1.45 (±0.22)	0.26 (±0.05)	110.9 (±17.1)	22 (±6.7)
	<sup>†</sup> 90% CI	102-110%		102-111%	
<b>t<sub>max</sub>**</b> (h)	100 mg/mL	3 (2-6)	4 (2-5)	2.5 (2-4.5)	3 (2-4.5)
	200 mg/mL	3.5 (2-6)	4.5 (2.5-6)	3.3 (2-5)	3 (2-5)
<b>AUC</b> (ss) (IU/mL or h* Δ sec)	100 mg/mL	14.26 (±2.93)	1.54 (±0.61)	1321 (±219)	
	200 mg/mL	15.43 (±2.96)	1.77 (±0.67)	1401 (±227)	
	90% CI	105-112%		103-109%	

\* Means ± SD at Day 5 and 90% Confidence Interval (CI) of the ratio  
\*\* Median (range)

**CLINICAL TRIALS**

**Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications:** Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of deep vein thrombosis or pulmonary embolism.

In a double-blind, parallel group study of patients undergoing elective cancer surgery of the gastrointestinal, urological, or gynecological tract, a total of 1116 patients were enrolled in the study, and 1115 patients were treated. Patients ranged in age from 32 to 97 years (mean age 67 years) with 52.7% men and 47.3% women. Patients were 98% Caucasian, 1.1% Black, 0.4% Oriental, and 0.4% others. Lovenox Injection 40 mg SC, administered once a day, beginning 2 hours prior to surgery and continuing for a maximum of 12 days after surgery, was comparable to heparin 5000 U every 8 hours SC in reducing the risk of deep vein thrombosis (DVT). The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis Following Abdominal Surgery**

Indication	Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC n (%)	Heparin 5000 U q8h SC n (%)
All Treated Abdominal Surgery Patients	555 (100)	560 (100)
Treatment Failures		
Total VTE <sup>1</sup> (%)	56 (10.1) (95% CI <sup>2</sup> : 8 to 13)	63 (11.3) (95% CI: 9 to 14)
DVT Only (%)	54 (9.7) (95% CI: 7 to 12)	61 (10.9) (95% CI: 8 to 13)

<sup>1</sup> VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin.

<sup>2</sup> CI = Confidence Interval

In a second double-blind, parallel group study, Lovenox Injection 40 mg SC once a day was compared to heparin 5000 U every 8 hours SC in patients undergoing colorectal surgery (one-third with cancer). A total of 1347 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 50.1 years) with 54.2% men and 45.8% women. Treatment was initiated approximately 2 hours prior to surgery and continued for approximately 7 to 10 days after surgery. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis Following Colorectal Surgery**

Indication	Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC n (%)	Heparin 5000 U q8h SC n (%)
All Treated Colorectal Surgery Patients	673 (100)	674 (100)
Treatment Failures		
Total VTE <sup>1</sup> (%)	48 (7.1) (95% CI <sup>2</sup> : 5 to 9)	45 (6.7) (95% CI: 5 to 9)
DVT Only (%)	47 (7.0) (95% CI: 5 to 9)	44 (6.5) (95% CI: 5 to 8)

<sup>1</sup> VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin.

<sup>2</sup> CI = Confidence Interval

**Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery:** Lovenox Injection has been shown to reduce the risk of post-operative deep vein thrombosis (DVT) following hip or knee replacement surgery.

In a double-blind study, Lovenox Injection 30 mg every 12 hours SC was compared to placebo in patients with hip replacement. A total of 100 patients were randomized in the study and all patients were treated. Patients ranged in age from 41 to 84 years (mean age 67.1 years) with 45% men and 55% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued for 10 to 14 days after surgery. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery**

Indication	Dosing Regimen	
	Lovenox Inj. 30 mg q12h SC n (%)	Placebo q12h SC n (%)
All Treated Hip Replacement Patients	50 (100)	50 (100)
Treatment Failures		
Total DVT (%)	5 (10) <sup>1</sup>	23 (46)
Proximal DVT (%)	1 (2) <sup>2</sup>	11 (22)

<sup>1</sup> p value versus placebo = 0.0002

<sup>2</sup> p value versus placebo = 0.0134

A double-blind, multicenter study compared three dosing regimens of Lovenox Injection in patients with hip replacement. A total of 572 patients were randomized in the study and 568 patients were treated. Patients ranged in age from 31 to 88 years (mean age 64.7 years) with 63% men and 37% women. Patients were 93% Caucasian, 6% Black, <1% Oriental, and 1% others. Treatment was initiated within two days after surgery and was continued for 7 to 11 days after surgery. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery**

Indication	Dosing Regimen		
	10 mg q.d. SC n (%)	30 mg q12h SC n (%)	40 mg q.d. SC n (%)
All Treated Hip Replacement Patients	161 (100)	208 (100)	199 (100)
Treatment Failures			
Total DVT (%)	40 (25)	22 (11) <sup>1</sup>	27 (14)
Proximal DVT (%)	17 (11)	8 (4) <sup>2</sup>	9 (5)

<sup>1</sup> p value versus Lovenox 10 mg once a day = 0.0008

<sup>2</sup> p value versus Lovenox 10 mg once a day = 0.0168

There was no significant difference between the 30 mg every 12 hours and 40 mg once a day regimens. In a double-blind study, Lovenox Injection 30 mg every 12 hours SC was compared to placebo in patients undergoing knee replacement surgery. A total of 132 patients were randomized in the study and 131 patients were treated, of which 99 had total knee replacement and 32 had either unicompartmental knee replacement or tibial osteotomy. The 99 patients with total knee replacement ranged in age from 42 to 85 years (mean age 70.2 years) with 36.4% men and 63.6% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued up to 15 days after surgery. The incidence of proximal and total DVT after surgery was significantly lower for Lovenox Injection compared to placebo. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis Following Total Knee Replacement Surgery**

Indication	Dosing Regimen	
	Lovenox Inj. 30 mg q12h SC n (%)	Placebo q12h SC n (%)
All Treated Total Knee Replacement Patients	47 (100)	52 (100)
Treatment Failures Total DVT (%)	5 (11) <sup>1</sup> (95% CI <sup>2</sup> : 1 to 21)	32 (62) (95% CI: 47 to 76)
Proximal DVT (%)	0 (0) <sup>3</sup> (95% Upper CL <sup>4</sup> : 5)	7 (13) (95% CI: 3 to 24)

<sup>1</sup> p value versus placebo = 0.0001  
<sup>2</sup> CI = Confidence Interval  
<sup>3</sup> p value versus placebo = 0.013  
<sup>4</sup> CL = Confidence Limit

Additionally, in an open-label, parallel group, randomized clinical study, Lovenox Injection 30 mg every 12 hours SC in patients undergoing elective knee replacement surgery was compared to heparin 5000 U every 8 hours SC. A total of 453 patients were randomized in the study and all were treated. Patients ranged in age from 38 to 90 years (mean age 68.5 years) with 43.7% men and 56.3% women. Patients were 92.5% Caucasian, 5.3% Black, 0.2% Oriental, and 0.4% others. Treatment was initiated after surgery and continued up to 14 days. The incidence of deep vein thrombosis was significantly lower for Lovenox Injection compared to heparin.

**Extended Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery:** In a study of extended prophylaxis for patients undergoing hip replacement surgery, patients were treated, while hospitalized, with Lovenox Injection 40 mg SC, initiated up to 12 hours prior to surgery for the prophylaxis of post-operative DVT. At the end of the peri-operative period, all patients underwent bilateral venography. In a double-blind design, those patients with no venous thromboembolic disease were randomized to a post-discharge regimen of either Lovenox Injection 40 mg (n = 90) once a day SC or to placebo (n = 89) for 3 weeks. A total of 179 patients were randomized in the double-blind phase of the study and all patients were treated. Patients ranged in age from 47 to 87 years (mean age 69.4 years) with 57% men and 43% women. In this population of patients, the incidence of DVT during extended prophylaxis was significantly lower for Lovenox Injection compared to placebo. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Extended Prophylaxis of Deep Vein Thrombosis Following Hip Replacement Surgery**

Indication (Post-Discharge)	Post-Discharge Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC n (%)	Placebo q.d. SC n (%)
All Treated Extended Prophylaxis Patients	90 (100)	89 (100)
Treatment Failures Total DVT (%)	6 (7) <sup>1</sup> (95% CI <sup>2</sup> : 3 to 14)	18 (20) (95% CI: 12 to 30)
Proximal DVT (%)	5 (6) <sup>3</sup> (95% CI: 2 to 13)	7 (8) (95% CI: 3 to 16)

<sup>1</sup> p value versus placebo = 0.008  
<sup>2</sup> CI = Confidence Interval  
<sup>3</sup> p value versus placebo = 0.537

In a second study, patients undergoing hip replacement surgery were treated, while hospitalized, with Lovenox Injection 40 mg SC, initiated up to 12 hours prior to surgery. All patients were examined for clinical signs and symptoms of venous thromboembolic (VTE) disease. In a double-blind design, patients without clinical signs and symptoms of VTE disease were randomized to a post-discharge regimen of either Lovenox Injection 40 mg (n = 131) once a day SC or to placebo (n = 131) for 3 weeks. A total of 262 patients were randomized in the study double-blind phase and all patients were treated. Patients ranged in age from 44 to 87 years (mean age 68.5 years) with 43.1% men and 56.9% women. Similar to the first study the incidence of DVT during extended prophylaxis was significantly lower for Lovenox Injection compared to placebo, with a statistically significant difference in both total DVT (Lovenox Injection 21 [16%] versus placebo 45 [34%]; p = 0.001) and proximal DVT (Lovenox Injection 8 [6%] versus placebo 28 [21%]; p = <0.001).

**Prophylaxis of Deep Vein Thrombosis (DVT) in Medical Patients with Severely Restricted Mobility During Acute Illness:** In a double blind multicenter, parallel group study, Lovenox Injection 20 mg or 40 mg once a day SC was compared to placebo in the prophylaxis of DVT in medical patients with severely restricted mobility during acute illness (defined as walking distance of <10 meters for ≤3 days). This study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or complicated chronic respiratory insufficiency (not requiring ventilatory support); acute infection (excluding septic shock); or acute rheumatic disorder [acute lumbar or sciatic pain, vertebral compression (due to osteoporosis or tumor), acute arthritic episodes of the lower extremities]. A total of 1102 patients were enrolled in the study, and 1073 patients were treated. Patients ranged in age from 40 to 97 years (mean age 73 years) with equal proportions of men and women. Treatment continued for a maximum of 14 days (median duration 7 days). When given at a dose of 40 mg once a day SC, Lovenox Injection significantly reduced the incidence of DVT as compared to placebo. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Deep Vein Thrombosis in Medical Patients With Severely Restricted Mobility During Acute Illness**

Indication	Dosing Regimen		
	Lovenox Inj. 20 mg q.d. SC n (%)	Lovenox Inj. 40 mg q.d. SC n (%)	Placebo n (%)
All Treated Medical Patients During Acute Illness	351 (100)	360 (100)	362 (100)
Treatment Failure <sup>1</sup> Total VTE <sup>2</sup> (%)	43 (12.3)	16 (4.4)	43 (11.9)
Total DVT (%)	43 (12.3) (95% CI <sup>3</sup> 8.8 to 15.7)	16 (4.4) (95% CI <sup>3</sup> 2.3 to 6.6)	41 (11.3) (95% CI <sup>3</sup> 8.1 to 14.6)
Proximal DVT (%)	13 (3.7)	5 (1.4)	14 (3.9)

<sup>1</sup> Treatment failures during therapy, between Days 1 and 14.  
<sup>2</sup> VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin.  
<sup>3</sup> CI = Confidence Interval<sup>1</sup>

At approximately 3 months following enrollment, the incidence of venous thromboembolism remained significantly lower in the Lovenox Injection 40 mg treatment group versus the placebo treatment group.

**Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction:** In a multicenter, double-blind, parallel group study, patients who recently experienced unstable angina or non-Q-wave myocardial infarction were randomized to either Lovenox Injection 1 mg/kg every 12 hours SC or heparin i.v. bolus (5000 U) followed by a continuous infusion (adjusted to achieve an aPTT of 55 to 85 seconds). A total of 3171 patients were enrolled in the study, and 3107 patients were treated. Patients ranged in age from 25-94 years (median age 64 years), with 33.4% of patients female and 66.6% male. Race was distributed as follows: 89.8% Caucasian, 4.8% Black, 2.0% Oriental, and 3.5% other. All patients were also treated with aspirin 100 to 325 mg per day. Treatment was initiated within 24 hours of the event and continued until clinical stabilization, revascularization procedures, or hospital discharge, with a maximal duration of 8 days of therapy. The combined incidence of the triple endpoint of death, myocardial infarction, or recurrent angina was lower for Lovenox Injection compared with heparin therapy at 14 days after initiation of treatment. The lower incidence of the triple endpoint was sustained up to 30 days after initiation of treatment. These results were observed in an analysis of both all-randomized and all-treated patients. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction (Combined Endpoint of Death, Myocardial Infarction, or Recurrent Angina)**

Indication	Dosing Regimen <sup>1</sup>		Reduction (%)	p Value
	Lovenox Inj. 1 mg/kg q12h SC n (%)	Heparin aPTT Adjusted i.v. Therapy n (%)		
All Treated Unstable Angina and Non-Q-Wave MI Patients	1578 (100)	1529 (100)		
Timepoint <sup>2</sup> 48 Hours	96 (6.1)	112 (7.3)	1.2	0.120
14 Days	261 (16.5)	303 (19.8)	3.3	0.017
30 Days	313 (19.8)	358 (23.4)	3.6	0.014

<sup>1</sup> All patients were also treated with aspirin 100 to 325 mg per day.  
<sup>2</sup> Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).

The combined incidence of death or myocardial infarction at all time points was lower for Lovenox Injection compared to standard heparin therapy, but did not achieve statistical significance. The efficacy data are provided below.

**Efficacy of Lovenox Injection in the Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction (Combined Endpoint of Death or Myocardial Infarction)**

Indication	Dosing Regimen <sup>1</sup>		Reduction (%)	p Value
	Lovenox Inj. 1 mg/kg q12h SC n (%)	Heparin aPTT Adjusted i.v. Therapy n (%)		
All Treated Unstable Angina and Non-Q-Wave MI Patients	1578 (100)	1529 (100)		
Timepoint <sup>2</sup> 48 Hours	16 (1.0)	20 (1.3)	0.3	0.126
14 Days	76 (4.8)	93 (6.1)	1.3	0.115
30 Days	96 (6.1)	118 (7.7)	1.6	0.069

<sup>1</sup> All patients were also treated with aspirin 100 to 325 mg per day.  
<sup>2</sup> Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).

In a survey one year following treatment, with information available for 92% of enrolled patients, the combined incidence of death, myocardial infarction, or recurrent angina remained lower for Lovenox Injection versus heparin (32.0% vs 35.7%). Urgent revascularization procedures were performed less frequently in the Lovenox Injection group as compared to the heparin group, 6.3% compared to 8.2% at 30 days (p = 0.047).

**Treatment of Deep Vein Thrombosis (DVT) with or without Pulmonary Embolism (PE):** In a multicenter, parallel group study, 900 patients with acute lower extremity DVT with or without PE were randomized to an inpatient (hospital) treatment of either (i) Lovenox Injection 1.5 mg/kg once a day SC, (ii) Lovenox Injection 1 mg/kg every 12 hours SC, or (iii) heparin i.v. bolus (5000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 60.7 years) with 54.7% men and 45.3% women. All patients also received warfarin sodium (dose adjusted according to PT to achieve an International Normalization Ratio [INR] of 2.0 to 3.0), commencing within 72 hours of initiation of Lovenox Injection or standard heparin therapy, and continuing for 90 days. Lovenox Injection or standard heparin therapy was administered for a minimum of 5 days and until the targeted warfarin sodium INR was achieved. Both Lovenox Injection regimens were equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism (DVT and/or PE). The efficacy data are provided below.

**Efficacy of Lovenox Injection in Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism**

Indication	Dosing Regimen <sup>1</sup>		
	Lovenox Inj. 1.5 mg/kg q.d. SC n (%)	Lovenox Inj. 1 mg/kg q12h SC n (%)	Heparin aPTT Adjusted i.v. Therapy n (%)
All Treated DVT Patients with or without PE	298 (100)	312 (100)	290 (100)
Patient Outcome Total VTE <sup>2</sup> (%)	13 (4.4) <sup>3</sup>	9 (2.9) <sup>3</sup>	12 (4.1)
DVT Only (%)	11 (3.7)	7 (2.2)	8 (2.8)
Proximal DVT (%)	9 (3.0)	6 (1.9)	7 (2.4)
PE (%)	2 (0.7)	2 (0.6)	4 (1.4)

<sup>1</sup> All patients were also treated with warfarin sodium commencing within 72 hours of Lovenox Injection or standard heparin therapy.  
<sup>2</sup> VTE = venous thromboembolic event (DVT and/or PE).  
<sup>3</sup> The 95% Confidence Intervals for the treatment differences for total VTE were: Lovenox Injection once a day versus heparin (-3.0 to 3.5) Lovenox Injection every 12 hours versus heparin (-4.2 to 1.7).

Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to Lovenox Injection or heparin. Patients who could not receive outpatient therapy were excluded from entering the study. Outpatient exclusion criteria included the following: inability to receive outpatient heparin therapy because of associated co-morbid conditions or potential for non-compliance and inability to attend follow-up visits as an outpatient because of geographic inaccessibility. Eligible patients could be treated in the hospital, but ONLY Lovenox Injection patients were permitted to go home on therapy (72%). A total of 501 patients were randomized in the study and all patients were treated. Patients ranged in age from 19 to 96 years (mean age 57.8 years) with 60.5% men and 39.5% women. Patients were randomized to either Lovenox Injection 1 mg/kg every 12 hours SC or heparin i.v. bolus (5000 IU) followed by a continuous infusion administered to achieve an aPTT of 60 to 85 seconds (in-patient treatment). All patients also received warfarin sodium as described in the previous study. Lovenox Injection or standard heparin therapy was administered for a minimum of 5 days. Lovenox Injection was equivalent to standard heparin therapy in reducing the risk of recurrent venous thromboembolism. The efficacy data are provided below.

**Efficacy of Lovenox Injection in Treatment of Deep Vein Thrombosis**

Indication	Dosing Regimen <sup>1</sup>	
	Lovenox Inj. 1 mg/kg q12h SC n (%)	Heparin aPTT Adjusted i.v. Therapy n (%)
All Treated DVT Patients	247 (100)	254 (100)
Patient Outcome Total VTE <sup>2</sup> (%)	13 (5.3) <sup>3</sup>	17 (6.7)
DVT Only (%)	11 (4.5)	14 (5.5)
Proximal DVT (%)	10 (4.0)	12 (4.7)
PE (%)	2 (0.8)	3 (1.2)

<sup>1</sup> All patients were also treated with warfarin sodium commencing on the evening of the second day of Lovenox Injection or standard heparin therapy.  
<sup>2</sup> VTE = venous thromboembolic event (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]).  
<sup>3</sup> The 95% Confidence Intervals for the treatment difference for total VTE was: Lovenox Injection versus heparin (-5.6 to 2.7).

**INDICATIONS AND USAGE**

- Lovenox Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:
  - in patients undergoing abdominal surgery who are at risk for thromboembolic complications;
  - in patients undergoing hip replacement surgery, during and following hospitalization;
  - in patients undergoing knee replacement surgery;
  - in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.
- Lovenox Injection is indicated for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
- Lovenox Injection is indicated for:
  - the **inpatient treatment** of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium;
  - the **outpatient treatment** of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium.

See **DOSE AND ADMINISTRATION: Adult Dosage** for appropriate dosage regimens.

**CONTRAINDICATIONS**

Lovenox Injection is contraindicated in patients with active major bleeding, in patients with thrombocytopenia associated with a positive *in vitro* test for anti-platelet antibody in the presence of enoxaparin sodium, or in patients with hypersensitivity to enoxaparin sodium. Patients with known hypersensitivity to heparin or pork products should not be treated with Lovenox Injection.

**WARNINGS**

Lovenox Injection is not intended for intramuscular administration. Lovenox Injection cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage. Each of these medicines has its own instructions for use.

**Lovenox Injection should be used with extreme caution in patients with a history of heparin-induced thrombocytopenia.**

**Hemorrhage:** Lovenox Injection, like other anticoagulants, should be used with extreme caution in conditions with increased risk of hemorrhage, such as bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.

**Cases of epidural or spinal hematomas have been reported with the associated use of Lovenox Injection and spinal/epidural anesthesia or spinal puncture resulting in long-term or permanent paralysis. The risk of these events is higher with the use of post-operative indwelling epidural catheters or by the concomitant use of additional drugs affecting hemostasis such as NSAIDs (see boxed WARNING; ADVERSE REACTIONS, Ongoing Safety Surveillance; and PRECAUTIONS, Drug Interactions).**

Major hemorrhages including retroperitoneal and intracranial bleeding have been reported. Some of these cases have been fatal.

Bleeding can occur at any site during therapy with Lovenox Injection. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site.

**Thrombocytopenia:** Thrombocytopenia can occur with the administration of Lovenox Injection. Moderate thrombocytopenia (platelet counts between 100,000/mm<sup>3</sup> and 50,000/mm<sup>3</sup>) occurred at a rate of 1.3% in patients given Lovenox Injection, 1.2% in patients given heparin, and 0.7% in patients given placebo in clinical trials.

Platelet counts less than 50,000/mm<sup>3</sup> occurred at a rate of 0.1% in patients given Lovenox Injection, in 0.2% of patients given heparin, and 0.4% of patients given placebo in the same trials.

Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm<sup>3</sup>, Lovenox Injection should be discontinued. Cases of heparin-induced thrombocytopenia with thrombosis have also been observed in clinical practice. Some of these cases were complicated by organ infarction, limb ischemia, or death.

**PRECAUTIONS**

**General:** Lovenox Injection should not be mixed with other injections or infusions.

Lovenox Injection should be used with care in patients with a bleeding diathesis, uncontrolled arterial hypertension or a history of recent gastrointestinal ulceration, diabetic retinopathy, and hemorrhage. Elderly patients and patients with renal insufficiency may show delayed elimination of enoxaparin. Lovenox Injection should be used with care in these patients. Adjustment of enoxaparin sodium dose may be considered for low weight (<45 kg) patients and/or for patients with severe renal impairment (creatinine clearance <30 mL/min). If thromboembolic events occur despite Lovenox Injection prophylaxis, appropriate therapy should be initiated.

**Laboratory Tests:** Periodic complete blood counts, including platelet count, and stool occult blood tests are recommended during the course of treatment with Lovenox Injection. When administered at recommended prophylaxis doses, routine coagulation tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) are relatively insensitive measures of Lovenox Injection activity and, therefore, unsuitable for monitoring. Anti-Factor Xa may be used to monitor the anticoagulant effect of Lovenox Injection in patients with significant renal impairment. If during Lovenox Injection therapy abnormal coagulation parameters or bleeding should occur, anti-Factor Xa levels may be used to monitor the anticoagulant effects of Lovenox Injection (see **CLINICAL PHARMACOLOGY: Pharmacodynamics**).

**Drug Interactions:** Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamol, or sulfipyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring (see **PRECAUTIONS: Laboratory Tests**).

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not mutagenic in *in vitro* tests, including the Ames test, mouse lymphoma cell forward mutation test, and human lymphocyte chromosomal aberration test, and the *in vivo* rat bone marrow chromosomal aberration test. Enoxaparin was found to have no effect on fertility or reproductive performance of male and female rats at SC doses up to 20 mg/kg/day or 141 mg/m<sup>2</sup>/day. The maximum human dose in clinical trials was 2.0 mg/kg/day or 78 mg/m<sup>2</sup>/day (for an average body weight of 70 kg, height of 170 cm, and body surface area of 1.8 m<sup>2</sup>).

**Pregnancy: Teratogenic Effects:** Pregnancy Category B: Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 30 mg/kg/day or 211 mg/m<sup>2</sup>/day and 410 mg/m<sup>2</sup>/day, respectively. There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Non-teratogenic Effects:** There have been a few spontaneous post-marketing reports of fetal death when pregnant women received Lovenox Injection. Causality of the cases has not been determined. In one case, placental hemorrhage and detachment were found in association with the fetal death. If Lovenox Injection is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lovenox Injection is administered to nursing women.

**Pediatric Use:** Safety and effectiveness of Lovenox Injection in pediatric patients have not been established. **Geriatric Use:** Over 2800 patients, 65 years and older, have received Lovenox Injection in pivotal clinical trials. The efficacy of Lovenox Injection in the elderly (≥65 years) was similar to that seen in younger patients (<65 years). The incidence of bleeding complications was similar between elderly and younger patients when 30 mg every 12 hours or 40 mg once a day doses of Lovenox Injection were employed. The incidence of bleeding complications was higher in elderly patients as compared to younger patients when Lovenox Injection was administered at doses of 1.5 mg/kg once a day or 1 mg/kg every 12 hours. The risk of Lovenox Injection-associated bleeding increased with age. Serious adverse events increased with age for patients receiving Lovenox Injection. Other clinical experience (including postmarketing surveillance and literature reports) has not revealed additional differences in the safety of Lovenox Injection between elderly and younger patients. Careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) is advised. Monitoring of geriatric patients with low body weight (<45 kg) and those predisposed to decreased renal function should be considered. (see **CLINICAL PHARMACOLOGY and General and Laboratory Tests** subsections of **PRECAUTIONS**)

**ADVERSE REACTIONS**

**Hemorrhage:** The incidence of major hemorrhagic complications during Lovenox Injection treatment has been low.

The following rates of major bleeding events have been reported during clinical trials with Lovenox Injection.

**Major Bleeding Episodes Following Abdominal and Colorectal Surgery<sup>1</sup>**

Indications	Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC	Heparin 5000 U q8h SC
Abdominal Surgery	n = 555 23 (4%)	n = 560 16 (3%)
Colorectal Surgery	n = 673 28 (4%)	n = 674 21 (3%)

<sup>1</sup> Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.

**Major Bleeding Episodes Following Hip or Knee Replacement Surgery<sup>1</sup>**

Indications	Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC	Heparin 15,000 U/24h SC
Hip Replacement Surgery Without Extended Prophylaxis <sup>2</sup>	n = 786 31 (4%)	n = 541 32 (6%)
Hip Replacement Surgery With Extended Prophylaxis		
Peri-operative Period <sup>3</sup>	n = 288 4 (2%)	
Extended Prophylaxis Period <sup>4</sup>	n = 221 0 (0%)	
Knee Replacement Surgery Without Extended Prophylaxis <sup>2</sup>	n = 294 3 (1%)	n = 225 3 (1%)

<sup>1</sup> Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major. In the knee replacement surgery trials, intraocular hemorrhages were also considered major hemorrhages.

<sup>2</sup> Lovenox Injection 30 mg every 12 hours SC initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery.

<sup>3</sup> Lovenox Injection 40 mg SC once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgery.

<sup>4</sup> Lovenox Injection 40 mg SC once a day for up to 21 days after discharge.

NOTE: At no time point were the 40 mg once a day pre-operative and the 30 mg every 12 hours post-operative hip replacement surgery prophylactic regimens compared in clinical trials.

Injection site hematomas during the extended prophylaxis period after hip replacement surgery occurred in 9% of the Lovenox Injection patients versus 1.8% of the placebo patients.

**Major Bleeding Episodes in Medical Patients With Severely Restricted Mobility During Acute Illness<sup>1</sup>**

Indications	Dosing Regimen		
	Lovenox Inj. <sup>2</sup> 20 mg q.d. SC	Lovenox Inj. <sup>2</sup> 40 mg q.d. SC	Placebo <sup>2</sup>
Medical Patients During Acute Illness	n = 351 1 (<1%)	n = 360 3 (<1%)	n = 362 2 (<1%)

<sup>1</sup> Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial.

<sup>2</sup> The rates represent major bleeding on study medication up to 24 hours after last dose.

**Major Bleeding Episodes in Unstable Angina and Non-Q-Wave Myocardial Infarction**

Indication	Dosing Regimen	
	Lovenox Inj. <sup>1</sup> 1 mg/kg q12h SC	Heparin <sup>1</sup> aPTT Adjusted i.v. Therapy
Unstable Angina and Non-Q-Wave MI <sup>2,3</sup>	n = 1578 17 (1%)	n = 1529 18 (1%)

<sup>1</sup> The rates represent major bleeding on study medication up to 12 hours after dose.

<sup>2</sup> Aspirin therapy was administered concurrently (100 to 325 mg per day).

<sup>3</sup> Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by ≥3 g/dL or transfusion of 2 or more units of blood products. Intraocular, retroperitoneal, and intracranial hemorrhages were always considered major.

**Major Bleeding Episodes in Deep Vein Thrombosis With or Without Pulmonary Embolism Treatment<sup>1</sup>**

Indication	Dosing Regimen <sup>2</sup>		
	Lovenox Inj. 1.5 mg/kg q.d. SC	Lovenox Inj. 1 mg/kg q12h SC	Heparin aPTT Adjusted i.v. Therapy
Treatment of DVT and PE	n = 298 5 (2%)	n = 559 9 (2%)	n = 554 9 (2%)

<sup>1</sup> Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and intracranial hemorrhages were always considered major.

<sup>2</sup> All patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of Lovenox Injection or standard heparin therapy and continuing for up to 90 days.

**Thrombocytopenia: see WARNINGS: Thrombocytopenia.**

**Elevations of Serum Aminotransferases:** Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients, respectively, during treatment with Lovenox Injection. Similar significant increases in aminotransferase levels have also been observed in patients and healthy volunteers treated with heparin and other low molecular weight heparins. Such elevations are fully reversible and are rarely associated with increases in bilirubin.

Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease, and pulmonary emboli, elevations that might be caused by drugs like Lovenox Injection should be interpreted with caution.

**Local Reactions:** Mild local irritation, pain, hematoma, ecchymosis, and erythema may follow SC injection of Lovenox Injection.

**Other:** Other adverse effects that were thought to be possibly or probably related to treatment with Lovenox Injection, heparin, or placebo in clinical trials with patients undergoing hip or knee replacement surgery, abdominal or colorectal surgery, or treatment for DVT and that occurred at a rate of at least 2% in the Lovenox Injection group, are provided below.

**Adverse Events Occurring at ≥2% Incidence in Lovenox Injection Treated Patients<sup>1</sup> Undergoing Abdominal or Colorectal Surgery**

Adverse Event	Dosing Regimen			
	Lovenox Inj. 40 mg q.d. SC n = 1228		Heparin 5000 U q8h SC n = 1234	
Hemorrhage	<1%	7%	<1%	6%
Anemia	<1%	3%	<1%	3%
Ecchymosis	0%	3%	0%	3%

<sup>1</sup> Excluding unrelated adverse events.



**Lovenox®  
(enoxaparin sodium) Injection**

**Lovenox®  
(enoxaparin sodium) Injection**

**Adverse Events Occurring at ≥2% Incidence in Lovenox Injection Treated Patients<sup>1</sup>  
Undergoing Hip or Knee Replacement Surgery**

**Note:** Lovenox Injection is available in two concentrations:

- 1 100 mg/mL Concentration:** 30 mg / 0.3 mL ampules, 30 mg / 0.3 mL and 40 mg / 0.4 mL prefilled single-dose syringes, 60 mg / 0.6 mL, 80 mg / 0.8 mL, and 100 mg / 1 mL prefilled, graduated, single-dose syringes.  
**2 150 mg/mL Concentration:** 120 mg / 0.8 mL and 150 mg / 1 mL prefilled, graduated, single-dose syringes.

**Adult Dosage:**

**Abdominal Surgery:** In patients undergoing abdominal surgery who are at risk for thromboembolic complications, the recommended dose of Lovenox Injection is **40 mg once a day** administered by SC injection with the initial dose given 2 hours prior to surgery. The usual duration of administration is 7 to 10 days; up to 12 days administration has been well tolerated in clinical trials.

**Hip or Knee Replacement Surgery:** In patients undergoing hip or knee replacement surgery, the recommended dose of Lovenox Injection is **30 mg every 12 hours** administered by SC injection. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of **40 mg once a day** SC, given initially 12 (±3) hours prior to surgery, may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, continued prophylaxis with Lovenox Injection 40 mg once a day administered by SC injection for 3 weeks is recommended. The usual duration of administration is 7 to 10 days; up to 14 days administration has been well tolerated in clinical trials.

**Medical Patients During Acute Illness:** In medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness, the recommended dose of Lovenox Injection is **40 mg once a day** administered by SC injection. The usual duration of administration is 6 to 11 days; up to 14 days of Lovenox Injection has been well tolerated in the controlled clinical trial.

**Unstable Angina and Non-Q-Wave Myocardial Infarction:** In patients with unstable angina or non-Q-wave myocardial infarction, the recommended dose of Lovenox Injection is **1 mg/kg administered SC every 12 hours** in conjunction with oral aspirin therapy (100 to 325 mg once daily). Treatment with Lovenox Injection should be prescribed for a minimum of 2 days and continued until clinical stabilization. To minimize the risk of bleeding following vascular instrumentation during the treatment of unstable angina, adhere precisely to the intervals recommended between Lovenox Injection doses. The vascular access sheath for instrumentation should remain in place for 6 to 8 hours following a dose of Lovenox Injection. The next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal. The site of the procedure should be observed for signs of bleeding or hematoma formation. The usual duration of treatment is 2 to 8 days; up to 12.5 days of Lovenox Injection has been well tolerated in clinical trials.

**Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism:** In **outpatient treatment**, patients with acute deep vein thrombosis without pulmonary embolism who can be treated at home, the recommended dose of Lovenox Injection is **1 mg/kg every 12 hours** administered SC. In **inpatient (hospital) treatment**, patients with acute deep vein thrombosis with pulmonary embolism or patients with acute deep vein thrombosis without pulmonary embolism (who are not candidates for outpatient treatment), the recommended dose of Lovenox Injection is **1 mg/kg every 12 hours** administered SC or **1.5 mg/kg once a day** administered SC at the same time every day. In both outpatient and inpatient (hospital) treatments, warfarin sodium therapy should be initiated when appropriate (usually within 72 hours of Lovenox Injection). Lovenox Injection should be continued for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (International Normalization Ratio 2.0 to 3.0). The average duration of administration is 7 days; up to 17 days of Lovenox Injection administration has been well tolerated in controlled clinical trials.

**Administration:** Lovenox Injection is a clear, colorless to pale yellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration.

When using Lovenox Injection ampules, to assure withdrawal of the appropriate volume of drug, the use of a tuberculin syringe or equivalent is recommended.

Lovenox Injection is administered by SC injection. It must not be administered by intramuscular injection. Lovenox Injection is intended for use under the guidance of a physician. Patients may self-inject only if their physician determines that it is appropriate and with medical follow-up, as necessary. Proper training in subcutaneous injection technique (with or without the assistance of an injection device) should be provided.

**Subcutaneous Injection Technique:** Patients should be lying down and Lovenox Injection administered by deep SC injection. To avoid the loss of drug when using the 30 and 40 mg prefilled syringes, do not expel the air bubble from the syringe before the injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection. An automatic injector, Lovenox EasyInjector™, is available for patients to administer Lovenox Injection packaged in 30 mg and 40 mg prefilled syringes. Please see directions accompanying the Lovenox EasyInjector™ automatic injection device.

**HOW SUPPLIED**

Lovenox® (enoxaparin sodium) Injection is available in two concentrations:

**100 mg/mL Concentration**

Dosage Unit / Strength <sup>1</sup>	Anti-Xa Activity <sup>2</sup>	Package Size (per carton)	Syringe Label Color	NDC # 0075-
<b>Ampules</b>				
30 mg / 0.3 mL	3000 IU	10 ampules	Medium Blue	0624-03
<b>Prefilled Syringes<sup>3</sup></b>				
30 mg / 0.3 mL	3000 IU	10 syringes	Medium Blue	0624-30
40 mg / 0.4 mL	4000 IU	10 syringes	Yellow	0620-40
<b>Graduated Prefilled Syringes<sup>3</sup></b>				
60 mg / 0.6 mL	6000 IU	10 syringes	Orange	0621-60
80 mg / 0.8 mL	8000 IU	10 syringes	Brown	0622-80
100 mg / 1 mL	10,000 IU	10 syringes	Black	0623-00

<sup>1</sup> Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox Injection ampules, 30 and 40 mg prefilled syringes, and 60, 80, 100 mg graduated prefilled syringes each contain **10 mg enoxaparin sodium per 0.1 mL Water for Injection.**

<sup>2</sup> Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.

<sup>3</sup> Each Lovenox Injection syringe is affixed with a 27 gauge x 1/2 inch needle.

**150 mg/mL Concentration**

Dosage Unit / Strength <sup>1</sup>	Anti-Xa Activity <sup>2</sup>	Package Size (per carton)	Syringe Label Color	NDC # 0075-
<b>Graduated Prefilled Syringes<sup>3</sup></b>				
120 mg / 0.8 mL	12,000 IU	10 syringes	Purple	2912-01
150 mg / 1 mL	15,000 IU	10 syringes	Navy Blue	2915-01

<sup>1</sup> Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox Injection 120 and 150 mg graduated prefilled syringes contain **15 mg enoxaparin sodium per 0.1 mL Water for Injection.**

<sup>2</sup> Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.

<sup>3</sup> Each Lovenox Injection graduated prefilled syringe is affixed with a 27 gauge x 1/2 inch needle.

Store at Controlled Room Temperature, 15-25°C (59-77°F) [see USP].

**Keep out of the reach of children.**

Lovenox Injection prefilled and graduated prefilled syringes manufactured in France. Lovenox Injection ampules manufactured in England.

**Aventis Pharmaceuticals Products Inc.**

BRIDGEWATER, NJ 08807

Prescribing information as of May 2001A.

50062180

Adverse Event	Dosing Regimen									
	Lovenox Inj. 40 mg q.d. SC		Lovenox Inj. 30 mg q12h SC		Heparin 15,000 U/24h SC		Placebo q12h SC			
	Severe	Total	Severe	Total	Severe	Total	Severe	Total	Severe	Total
	n = 288 <sup>2</sup>		n = 131 <sup>3</sup>		n = 1080		n = 766		n = 115	
Fever	0%	8%	0%	0%	<1%	5%	<1%	4%	0%	3%
Hemorrhage	<1%	13%	0%	5%	<1%	4%	1%	4%	0%	3%
Nausea					<1%	3%	<1%	2%	0%	2%
Anemia	0%	16%	0%	<2%	<1%	2%	2%	5%	<1%	7%
Edema					<1%	2%	<1%	2%	0%	2%
Peripheral edema	0%	6%	0%	0%	<1%	3%	<1%	4%	0%	3%

<sup>1</sup> Excluding unrelated adverse events.

<sup>2</sup> Data represents Lovenox Injection 40 mg SC once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received Lovenox Injection peri-operatively in an unblinded fashion in one clinical trial.

<sup>3</sup> Data represents Lovenox Injection 40 mg SC once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial.

**Adverse Events Occurring at ≥2% Incidence in Lovenox Injection Treated Medical Patients<sup>1</sup>  
With Severely Restricted Mobility During Acute Illness**

Adverse Event	Dosing Regimen	
	Lovenox Inj. 40 mg q.d. SC n = 360	Placebo q.d. SC n = 362
Dyspnea	3.3	5.2
Thrombocytopenia	2.8	2.8
Confusion	2.2	1.1
Diarrhea	2.2	1.7
Nausea	2.5	1.7

<sup>1</sup> Excluding unrelated and unlikely adverse events.

**Adverse Events in Lovenox Injection Treated Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction:** Non-hemorrhagic clinical events reported to be related to Lovenox Injection therapy occurred at an incidence of ≤1%.

Non-major hemorrhagic episodes, primarily injection site ecchymoses and hematomas, were more frequently reported in patients treated with SC Lovenox Injection than in patients treated with i.v. heparin. Serious adverse events with Lovenox Injection or heparin in a clinical trial in patients with unstable angina or non-Q-wave myocardial infarction that occurred at a rate of at least 0.5% in the Lovenox Injection group, are provided below (irrespective of relationship to drug therapy).

**Serious Adverse Events Occurring at ≥0.5% Incidence in Lovenox Injection Treated Patients  
With Unstable Angina or Non-Q-Wave Myocardial Infarction**

Adverse Event	Dosing Regimen	
	Lovenox Inj. 1 mg/kg q12h SC n = 1578 n (%)	Heparin aPTT Adjusted i.v. Therapy n = 1529 n (%)
Atrial fibrillation	11 (0.70)	3 (0.20)
Heart failure	15 (0.95)	11 (0.72)
Lung edema	11 (0.70)	11 (0.72)
Pneumonia	13 (0.82)	9 (0.59)

**Adverse Events Occurring at ≥2% Incidence in Lovenox Injection Treated Patients<sup>1</sup>  
Undergoing Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism**

Adverse Event	Dosing Regimen					
	Lovenox Inj. 1.5 mg/kg q.d. SC		Lovenox Inj. 1 mg/kg q12h SC		Heparin aPTT Adjusted i.v. Therapy n = 544	
	Severe	Total	Severe	Total	Severe	Total
	n = 298		n = 559		n = 544	
Injection Site Hemorrhage	0%	5%	0%	3%	<1%	<1%
Injection Site Pain	0%	2%	0%	2%	0%	0%
Hematuria	0%	2%	0%	<1%	<1%	2%

<sup>1</sup> Excluding unrelated adverse events.

**Ongoing Safety Surveillance:** Since 1993, there have been more than 68 reports of epidural or spinal hematoma formation with concurrent use of Lovenox Injection and spinal/epidural anesthesia or spinal puncture. The majority of patients had a post-operative indwelling epidural catheter placed for analgesia or received additional drugs affecting hemostasis such as NSAIDs. Many of the epidural or spinal hematomas caused neurologic injury, including long-term or permanent paralysis. Because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made.

**Other Ongoing Safety Surveillance Reports:** local reactions at the injection site (i.e., skin necrosis, nodules, inflammation, oozing), systemic allergic reactions (i.e., pruritus, urticaria, anaphylactoid reactions), vesiculobullous rash, purpura, thrombocytosis, and thrombocytopenia with thrombosis (see **WARNINGS, Thrombocytopenia**). Very rare cases of hyperlipidemia have been reported, with one case of hyperlipidemia, with marked hypertriglyceridemia, reported in a diabetic pregnant woman; causality has not been determined.

**OVERDOSAGE**

**Symptoms/Treatment:** Accidental overdosage following administration of Lovenox Injection may lead to hemorrhagic complications. Injected Lovenox Injection may be largely neutralized by the slow i.v. injection of protamine sulfate (1% solution). The dose of protamine sulfate should be equal to the dose of Lovenox Injection injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Lovenox Injection. A second injection of 0.5 mg protamine sulfate per 1 mg of Lovenox Injection may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged. However, even with higher doses of protamine, the aPTT may remain more prolonged than under normal conditions found following administration of heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60%). Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions, often resembling anaphylaxis, have been reported with protamine sulfate, it should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available. For additional information consult the labeling of Protamine Sulfate Injection, USP, products. A single SC dose of 46.4 mg/kg enoxaparin was lethal to rats. The symptoms of acute toxicity were ataxia, decreased motility, dyspnea, cyanosis, and coma.

**DOSE AND ADMINISTRATION**

All patients should be evaluated for a bleeding disorder before administration of Lovenox Injection, unless the medication is needed urgently. Since coagulation parameters are unsuitable for monitoring Lovenox Injection activity, routine monitoring of coagulation parameters is not required (see **PRECAUTIONS, Laboratory Tests**).

